Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | PARL | Q9H300 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.34 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinchlorimide SCHEMBL7000475 | 0.82 | PARL (0.39) | PARLPOLBRAF1MAPK3MAP3K8 | |
| SCHEMBL11197983 | 0.79 | CYP3A4 (0.50) | CYP3A4TDP1ESR1ESR2PARL | |
| SCHEMBL313161 | 0.79 | CYP3A4 (0.50) | CYP3A4TDP1ESR1ESR2PARL | |
| Succinchlorimide SCHEMBL1465495 | 0.74 | BRD4 (0.30) | — | |
| Succinchlorimide SCHEMBL5897812 | 0.74 | — | — | |
| Succinchlorimide SCHEMBL72 | 0.74 | — | — | |
| Oxygen SCHEMBL11268842 | 0.71 | TDP1 (0.75) | CYP3A4TDP1ESR1ESR2ALDH1A1 | |
| Cyclopentanone SCHEMBL9343959 | 0.71 | CYP3A4 (0.57) | CYP3A4TDP1ESR1ESR2ALDH1A1 | |
| Succinchlorimide SCHEMBL31009667 | 0.71 | — | — | |
| SCHEMBL1951204 | 0.71 | TDP1 (0.86) | CYP3A4TDP1ESR1ESR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105541793-A | Synthetic method of trelagliptin, trelagliptin synthesized through method and trelagliptin synthesis intermediate | HEBEI GUOLONG PHARMACEUTICAL CO LTD | 2016-05-04 | — | — | CN | claimed |
| CN-101031573-B | Heteroatoms-containing tricyclic compounds | NOVARTIS AG | 2010-06-09 | — | — | CN | claimed |
| EP-3559007-B1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO CO LTD (JP) | 2023-08-16 | — | — | EP | disclosed |
| CN-110167946-B | Sulfonamide compounds having TNAP inhibitory activity | 第一三共株式会社 | 2022-04-08 | — | — | CN | disclosed |
| US-11168101-B2 | Crystal of cyclic phosphonic acid sodium salt and method for manufacturing same | OTSUKA CHEMICAL CO., LTD. (JP) | 2021-11-09 | — | — | US | disclosed |
| CN-106661065-B | Crystal of cyclic phosphonic acid sodium salt and method for producing same | 大塚化学株式会社 | 2021-09-24 | — | — | CN | disclosed |
| US-11046710-B2 | Sulfonamide compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| EP-3483169-B1 | CRYSTAL OF CYCLIC PHOSPHONIC ACID SODIUM SALT AND METHOD FOR MANUFACTURING SAME | OTSUKA CHEMICAL CO LTD (JP) | 2021-05-26 | — | — | EP | disclosed |
| US-11014939-B2 | — | — | 2021-05-25 | — | — | US | disclosed |
| US-10941169-B2 | Crystal of cyclic phosphonic acid sodium salt and method for manufacturing same | OTSUKA CHEMICAL CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| US-10774100-B2 | Crystal of cyclic phosphonic acid sodium salt and method for manufacturing same | OTSUKA CHECMIAL CO., LTD. (JP) | 2020-09-15 | — | — | US | disclosed |
| EP-1471056-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | Takeda Chemical Industries, Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
| EP-1219631-A1 | ANTIANDROGEN AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-6372800-B1 | IMMUNOSUPPRESSIVE EFFECT AND IS USEFUL AS AN INHIBITOR FOR THE REJECTION REACTION OCCURRING IN ORGAN OR BONE MARROW TRANSPLANTATION, AND AS A PREVENTIVE OR REMEDY FOR ARTICULAR RHEUMATISM, ATOPIC ECZEMA (DERMATITIS), BEHCET'S DISEASE, | MITSUBISHI PHARMA CORPORATION (JP) | 2002-04-16 | — | — | US | disclosed |
| EP-0778263-B1 | BENZENE COMPOUND AND MEDICINAL USE THEREOF | WELFIDE CORP (JP) | 2002-01-09 | — | — | EP | disclosed |
| US-6187821-B1 | SUCH AS 2-AMINO-2-(3-(4-HEPTYLPHENYL)PROPYL)BUTANE-1,4-DIOL; IMMUNOSUPPRESSANT; ADMINISTERING TO TREAT OR PREVENT AUTOIMMUNE DISEASES AND ALLERGIES | WELFIDE CORPORATION (JP) | 2001-02-13 | — | — | US | disclosed |
| US-5948820-A | IMMUNOSUPPRESSANT; PREVENT REJECTION OF ORGAN TRANSPLANT;AUTOIMMUNE DISEASES; MULTIPLE SCLEROSIS; LUPUS; ANTIALLERGENS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| US-5686021-A | Liquid crystal display device, methods of producing and driving the liquid crystal display device, and liquid crystal composition | IDEMITSU KOSAN CO., LTD. (JP) | 1997-11-11 | — | — | US | disclosed |
| EP-0778263-A1 | BENZENE COMPOUND AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996026207-A1 | THIAZOLIDINE AND OXAZOLIDINE INDOLES WITH HYPOCLYCEMIC ACTIVITY | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168101-B2 | Crystal of cyclic phosphonic acid sodium salt and method for manufacturing same | PPM1A, PPP1CA, PPM1G | CYP3A4 4066/4885TDP1 2342/4885ESR1 4776/4885 |
| US-10774100-B2 | Crystal of cyclic phosphonic acid sodium salt and method for manufacturing same | PPM1A, PPM1G, PPP1CA | CYP3A4 4126/4885TDP1 3065/4885ESR1 4736/4885 |
| US-11014939-B2 | — | ALPI, ALPP, ACER2 | CYP3A4 1696/4885TDP1 2371/4885ESR1 4388/4885 |
| US-10941169-B2 | Crystal of cyclic phosphonic acid sodium salt and method for manufacturing same | PPM1A, PPP1CA, PPM1G | CYP3A4 3730/4885TDP1 3111/4885ESR1 4806/4885 |
| US-11046710-B2 | Sulfonamide compounds | ALPI, ASAH2, STS | CYP3A4 1108/4885TDP1 2478/4885ESR1 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.